| |
Greg,
>> I must say that I was not that impressed with the current Board of Directors
as there does not seem to be much depth with regard to the line of work of
the company. Can't help but wonder what Glen Sather knows about medical
research for example, given his line of work as a hockey coach and General
Manager of the Edmonton Oilers?
The Annual Report also gives almost no information about what kinds of
people are employed by the company and what work they are actually engaged
in. <<
I have not received my copy of the new Annual Report, so the lates info I have access to, is on the home page: dimethaid.com .
Regarding competence of those in the driver's seat, what do you think of the latest newsrelease, of wich I am posting an excerpt below?
Excerpt:
__________________________________________
DIMETHAID RESEARCH ESTABLISHES SCIENTIFIC ADVISORY
BOARD -APPOINTS TWO PROMINENT SCIENTISTS
Markham, Ont., August 28, 1997 - Rebecca Keeler, President and
CEO of Dimethaid Research Inc. (TSE: DMX) announced today that the
Company has created a Scientific Advisory Board. The first two
appointments to the Board are Dr. Angela Mailis of Toronto and Dr. Gary
J. Bennett of Philadelphia.
Dr. Angela Mailis is currently the Director of the Comprehensive Pain
Program and Division Head of Physical Medicine & Rehabilitation at The
Toronto Hospital. She is also an Associate Professor at the Department
of Medicine at the University of Toronto and Playfair Neuroscience Unit
Associate at The Toronto Hospital and University of Toronto. She was
Director of the Pain Investigation Unit at The Toronto Hospital for 15
years up until it expanded recently to become the Comprehensive Pain
Program. Dr. Mailis has published in many scientific journals. Her
current research focus is on human neuropathic pain, description of
human pain syndromes, pain demographics and drug trials for pain. She
received her Medical Degree from, and was a Gold Medalist at, the
University of Athens Medical School, and her Master of Science Degree
from the University of Toronto. She is a specialist in Physical Medicine
and Rehabilitation and has devoted her carrier exclusively to the
diagnosis and treatment of pain.
Dr. Gary J. Bennett is the Director of Pain Research, Allegheny Health
Education Research Foundation Chronic Pain Clinic, and Director of the
Quantitative Sensory Testing and Autonomic Nervous System Testing
Laboratories, Department of Neurology, Allegheny University of the
Health Sciences in Philadelphia, PA. Dr. Bennett was awarded the
Frederick W.L. Kerr Basic Science Research Award by the American Pain
Society in 1996, has been associate editor of PAIN, the journal of the
International Association on the Study of Pain since 1986 and the
co-editor-in-chief of The Pain Medicine Journal Club Journal since
1994. He received his Ph.D. from Virginia Commonwealth University,
and is one of the world's best known basic scientists in the field of
pain research.
"We are honoured to have such esteemed scientists contribute to the
development of our platform transdermal drug delivery system," Mrs.
Keeler stated. "As we move closer to the commercialization of
PENNSAID, our arthritis pain relief medication, we want to not only
explore new indications for this drug, but also the use of our drug
delivery system for other pain medications. The combined expertise
from these two individuals in the area of pain will be an invaluable
asset to us as we move forward - we will value their contributions
greatly," Mrs. Keeler added.
_________________________________________
Thanks,
Bounced Czech |
|
